Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 7
2003 4
2004 4
2005 6
2006 4
2007 5
2008 3
2009 2
2010 13
2011 10
2012 5
2013 9
2014 7
2015 7
2016 4
2017 7
2018 3
2019 9
2020 5
2021 9
2022 12
2023 9
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Trametinib sensitizes KRAS-mutant lung adenocarcinoma tumors to PD-1/PD-L1 axis blockade via Id1 downregulation.
Puyalto A, Rodríguez-Remírez M, López I, Macaya I, Guruceaga E, Olmedo M, Vilalta-Lacarra A, Welch C, Sandiego S, Vicent S, Valencia K, Calvo A, Pio R, Raez LE, Rolfo C, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: calvo a. Mol Cancer. 2024 Apr 20;23(1):78. doi: 10.1186/s12943-024-01991-3. Mol Cancer. 2024. PMID: 38643157 Free PMC article.
Polymeric nanocapsules loaded with poly(I:C) and resiquimod to reprogram tumor-associated macrophages for the treatment of solid tumors.
Anfray C, Varela CF, Ummarino A, Maeda A, Sironi M, Gandoy S, Brea J, Loza MI, León S, Calvo A, Correa J, Fernandez-Megia E, Alonso MJ, Allavena P, Crecente-Campo J, Andón FT. Anfray C, et al. Among authors: calvo a. Front Immunol. 2024 Jan 8;14:1334800. doi: 10.3389/fimmu.2023.1334800. eCollection 2023. Front Immunol. 2024. PMID: 38259462 Free PMC article.
A novel [89Zr]-anti-PD-1-PET-CT to assess response to PD-1/PD-L1 blockade in lung cancer.
Puyalto A, Rodríguez-Remírez M, López I, Iribarren F, Simón JA, Ecay M, Collantes M, Vilalta-Lacarra A, Francisco-Cruz A, Solórzano JL, Sandiego S, Peñuelas I, Calvo A, Ajona D, Gil-Bazo I. Puyalto A, et al. Among authors: calvo a. Front Immunol. 2023 Sep 28;14:1272570. doi: 10.3389/fimmu.2023.1272570. eCollection 2023. Front Immunol. 2023. PMID: 37841258 Free PMC article.
PTEN Loss Confers Resistance to Anti-PD-1 Therapy in Non-Small Cell Lung Cancer by Increasing Tumor Infiltration of Regulatory T Cells.
Exposito F, Redrado M, Houry M, Hastings K, Molero-Abraham M, Lozano T, Solorzano JL, Sanz-Ortega J, Adradas V, Amat R, Redin E, Leon S, Legarra N, Garcia J, Serrano D, Valencia K, Robles-Oteiza C, Foggetti G, Otegui N, Felip E, Lasarte JJ, Paz-Ares L, Zugazagoitia J, Politi K, Montuenga L, Calvo A. Exposito F, et al. Among authors: calvo a. Cancer Res. 2023 Aug 1;83(15):2513-2526. doi: 10.1158/0008-5472.CAN-22-3023. Cancer Res. 2023. PMID: 37311042
Targeted siRNA lipid nanoparticles for the treatment of KRAS-mutant tumors.
Anthiya S, Öztürk SC, Yanik H, Tavukcuoglu E, Şahin A, Datta D, Charisse K, Álvarez DM, Loza MI, Calvo A, Sulheim E, Loevenich S, Klinkenberg G, Schmid R, Manoharan M, Esendağlı G, Alonso MJ. Anthiya S, et al. Among authors: calvo a. J Control Release. 2023 May;357:67-83. doi: 10.1016/j.jconrel.2023.03.016. Epub 2023 Mar 28. J Control Release. 2023. PMID: 36921725 Free article.
125 results